Revised terminal half‐life of nonacog alfa as derived from extended sampling data: A real‐world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis-Reference-Cited by-同舟云学术

Revised terminal half‐life of nonacog alfa as derived from extended sampling data: A real‐world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis

Published:2022-04-14 Issue:4 Volume:28 Page:542-547
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Tardy Brigitte¹²³,Lambert Thierry⁴,Chamouni Pierre⁵^ORCID,Montmartin Aurélie²,Trossaert Marc⁶^ORCID,Claeyssens Ségolène⁷,Berger Claire¹,Ardillon Laurent⁸,Gay Valérie⁹,Delavenne Xavier²^ORCID,Harroche Annie¹⁰,Chelle Pierre¹¹

Affiliation:

1. Centre de Ressources et de Compétence Maladies hémorragiques CHU Saint‐Etienne Hôpital Nord Saint‐Etienne France

2. Sainbiose, Inserm, U1059 Université Lyon Saint‐Etienne France

3. Inserm, CIC 1408 CHU Saint‐Etienne Hôpital Nord Saint‐Etienne France

4. Centre de Référence Maladies hémorragiques CHU Paris Sud‐Hôpital de Bicêtre Le Kremlin‐Bicêtre France

5. Laboratoire d'Hématologie Institut de Biologie Clinique CHU de Rouen Rouen France

6. Centre de Ressources et de Compétence Maladies hémorragiques CHU de Nantes Nantes France

7. Centre de Ressources et de Compétence Maladies hémorragiques CHU Toulouse‐Hôpital Purpan Toulouse France

8. Centre de Ressources et de Compétence Maladies hémorragiques CHU Tours‐Hôpital Trousseau Tours France

9. Centre de Ressources et de Compétence Maladies hémorragiques Centre hospitalier Métropole Savoie Chambéry France

10. Centre de Référence Maladies hémorragiques Hôpital Necker Enfants‐Malades Université Paris Descartes Paris France

11. School of Pharmacy University of Waterloo Waterloo Canada

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14560

Reference18 articles.

1. Reformulated BeneFix�: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B

2. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis

3. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring

4. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B

5. Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators;Blood Reviews;2023-09

2. Managing Relevant Clinical Conditions of Hemophilia A/B Patients;Hematology Reports;2023-06-07

3. Hemophilic Arthropathy: Barriers to Early Diagnosis and Management;Journal of Blood Medicine;2022-10